Trials / Completed
CompletedNCT04279405
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
A Phase 1b Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Recurrent and/or Refractory B-cell Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor. eligible participants will initiate oral therapy with YY-20394 at a starting dose of 80mg taken once per day. treatment with YY-20394 can continue in compliant participants as long as the study is still ongoing and the participants appear to benefiting from treatment with acceptable safety.
Conditions
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YY-20394 | YY-20394 80mg tablet administered orally once daily |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2021-09-30
- Completion
- 2023-06-01
- First posted
- 2020-02-21
- Last updated
- 2024-06-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04279405. Inclusion in this directory is not an endorsement.